Intest Res Search

CLOSE


Published online November 2, 2017.
Efficacy and safety of ustekinumab in Japanese patients with moderately to severely active Crohn's disease
This issue chosen by the Editor of Intestinal Research is the subpopulation analysis of phase 3 induction and maintenance studies about the efficacy and safety of the Ustekinumab for Crohn's disease (CD) performed by Toshifumi Hibi et al.

The phase 3 ustekinumab study about the moderate to severe CD was performed previously. It is comprised of two 8-week induction studies (UNITI-1 and UNITI-2) and 44-week randomized maintenance study (IM-UNITI). In this previous study, intravenous ustekinumab had an effect of remission induction and remission maintenance in patients who had a clinical response to induction therapy.

This issue reported the efficacy and safety of ustekinumab from the UNITI-1, UNITI-2, and IM-UNITI global studies in a Japanese subpopulation. For Japanese patients, ustekinumab was also effective as induction and maintenance treatments.

Read more about the efficacy and safety of ustekinumab in CD.

In addition to these articles, read other articles about biologic therapy in patients with CD.

Best regards,
Related article
  • SCImago Journal & Country Rank
  • AOCC 2018
  • CSIBD
  • JSIBD
  • kasid
  • TSIBD
  • CCF
  • PubMed Central
  • PubMed
  • KoreaMed
  • KoMCI
  • Scopus
  • Directory of Open Access Journals (DOAJ)
  • Science Central
  • GoogleScholar
  • EBSCO
  • Similarity Check
  • Crossref Cited-by Linking
  • CrossMark
  • Funder Registry
  • ORCID
  • COPE
  • KOFST
  • TrendMD


ABOUT
ARTICLE CATEGORY

Browse all articles >

BROWSE ARTICLES
EDITORIAL POLICY
AUTHOR INFORMATION
Editorial Office
Room 305, Lotte Gold Rose II, 31 Seolleung-ro 86-gil, Gangnam-gu, Seoul 06193, Korea
Tel: +82-2-957-6145    Fax: +82-2-957-6146    E-mail: thekasid@irjournal.org                

Copyright © 2019 by Korean Association for the Study of Intestinal Diseases. All rights reserved.

Developed in M2community

Close layer
prev next